Table 1 Clinical and molecular characteristics of the CRC subgroups stratified by peroxisome score and TIM3 expression
|  | n = 1149 | Group I + II (PeroxisomeHigh) n = 574 (50%) | Group III (PerLowTIM3High) n = 263 (23%) | Group IV (PerLowTIM3Low) n = 312 (27%) | p |
|---|---|---|---|---|---|
Age (years) | |||||
 <  65 | 445 | 239 (54%) | 86 (19%) | 120 (27%) |  |
 ≥ 65 | 704 | 335 (48%) | 177 (25%) | 192 (27%) | 0.048 |
Gender | |||||
 Female | 526 | 261 (49%) | 119 (23%) | 146 (28%) |  |
 Male | 623 | 313 (50%) | 144 (23%) | 166 (27%) | 0.913 |
Stage | |||||
 I | 133 | 74 (56%) | 18 (14%) | 41 (31%) |  |
 II | 474 | 253 (53%) | 110 (23%) | 111 (23%) |  |
 III | 371 | 169 (46% | 94 (25%) | 108 (29%) |  |
 IV | 147 | 65 (44%) | 37 (25%) | 45 (31%) | 0.020 |
Location | |||||
 Left colon, rectum | 549 | 277 (50%) | 114 (21%) | 158 (29%) |  |
 Right colon | 578 | 146 (25%) | 146 (25%) | 286 (50%) | 0.149 |
Microsatellite | |||||
 MSI | 150 | 64 (43%) | 66 (44%) | 20 (13%) |  |
 MSS | 949 | 480 (51%) | 178 (19%) | 291 (31%) | < 0.001 |
CMS | |||||
 CMS1 | 160 | 65 (41%) | 77 (48%) | 18 (11%) |  |
 CMS2 | 445 | 274 (62%) | 42 (9%) | 129 (29%) |  |
 CMS3 | 136 | 89 (65%) | 10 (7%) | 37 (27%) |  |
 CMS4 | 253 | 74 (29%) | 106 (42%) | 73 (29%) |  |
 Indeterminate | 106 | 54 (51%) | 24 (23%) | 28 (26%) | < 0.001 |
KRAS status | |||||
 Mutated | 374 | 192 (51%) | 92 (25%) | 90 (24%) |  |
 Wild-type | 664 | 314 (47%) | 156 (23%) | 194 (29%) | 0.197 |
BRAF status | |||||
Mutated | 102 | 36 (35%) | 48 (47%) | 18 (18%) | Â |
Wild-type | 903 | 455 (50%) | 192 (21%) | 256 (28%) | < 0.001 |
TP53 status | |||||
 Mutated | 496 | 222 (45%) | 97 (20%) | 177 (36%) |  |
 Wild-type | 351 | 191 (54%) | 76 (22%) | 84 (24%) | 0.001 |
CIMP | |||||
 High | 164 | 64 (39%) | 70 (43%) | 30 (18%) |  |
 Low | 771 | 420 (54%) | 159 (21%) | 192 (25%) | < 0.001 |